Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity

Determination of the Relationship Between Nesfatin-1 Levels and Energy Intake Levels of Patients With Type 2 Diabetes, Insulin Resistance and Obesity

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04298515

Enrollment

180

Registered

2020-03-06

Start date

2020-03-02

Completion date

2021-03-31

Last updated

2020-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Nesfatin-1, Obesity, Type 2 Diabetes

Keywords

Type 2 diabetes, Insulin resistance, Obesity, Nesfatin-1

Brief summary

This research was planned to determine the level of nesfatin-1, known as satiety hormone, in type 2 diabetes, insulin diabetes and obesity patients and to determine whether there is a relationship between patients' energy intake levels. Additionally, it was aimed to evaluate the relationship between patients' nesfatin-1 values and serum glucose, insulin, lipid concentrations.

Detailed description

Nesfatin-1 levels of patients with type 2 diabetes, insulin resistance and obesity will be measured. In addition, patients' daily food consumption will be taken and the amount of energy they receive will be calculated daily. The relationship between the level of nesfatin-1 in the blood and the energy received will be examined.

Interventions

DIAGNOSTIC_TESTNesfatin-1

Blood will be taken from the patients on an empty stomach for measuring nesfatin-1 level

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to 79 Years

Healthy volunteers

Yes

Inclusion criteria

* Type 2 diabetes * Insulin resistance * Obesity disease

Exclusion criteria

* Pediatric individuals * All patients who are hospitalized, * Liver disease * Cancer patients * Disease related to the gastrointestinal tract * Nephrological disease such as chronic kidney failure, acute kidney failure, nephrotic syndrome * Neurological disease

Design outcomes

Primary

Measure	Time frame	Description
Nefratin-1 in type 2 diabetes	1 day (Blood will be drawn from patients once)	Blood will be drawn from type 2 diabates patients after 12 hours of fasting (n=45)
Nefratin-1 in obesity	1 day (Blood will be drawn from patients once)	Blood will be drawn from obesity patients after 12 hours of fasting (n=45)
Nefratin-1 in insulin resistance	1 day (Blood will be drawn from patients once)	Blood will be drawn from insulin resistance patients after 12 hours of fasting (n=45)

Countries

Turkey (Türkiye)

Contacts

Primary ContactGülin Öztürk Özkan, Assis Prof

glnzturk@gmail.com02162803333

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026